Proceedings of The Physiological Society

University of Oxford (2011) Proc Physiol Soc 23, PC54

Poster Communications

Treatment of Glioma Using Liposomes Generated From Alcohol-based Proliposomes

S. Jaiswal1,2, G. Manoharran1,2, W. Ahmed1,3, A. Elhissi1,2

1. School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, United Kingdom. 2. Institute of Nanotechnology and Bioengineering, University of Central Lancashire, Preston, United Kingdom. 3. School of Computing, Engineering and Physical Sciences, University of Central Lancashire, Preston, United Kingdom.

Every year approximately 2% of cancer patients in the UK are diagnosed with glioma (Garside et al., 2005). All the treatments available pose risks such as surgical procedures which are dreadful and very painful, radiation therapy damages normal cells and in chemotherapy some of the drugs cannot get into the brain because of the blood brain barrier. Unfortunately, glioma can regenerate even after the treatment. Liposome has the interesting properties of entrapping hydrophilic and hydrophobic drugs and targeting tumours cells. Liposomes are vesicles made of phospholipid molecules which are similar to biological membranes and hence biocompatible and biodegradable (Katare et al., 1990; Crommelin and Sindelar, 2002). The major drawback of conventionally prepared liposomes is that, they are chemically and physically unstable and they are difficult to manufacture on a large scale. Stability problems can be avoided by formulation of liposomes using the solvent based proliposome method (Perrett et al., 1991). The resultant liposomes provide high entrapment of hydrophilic agents and can also be prepared on a large scale. The aim of our project is to use herbal extracts such as Taxol, Crude M. Charantia and Alpha-beta momorcharin binded to the phosphatidylcholine to manufacture solvent-based proliposome which can be used to generate liposomes when the aqueous phase is added. The resultant size of the vesicles was compared with the conventional method of producing liposome and also with the increasing concentration of the model anticancer drug. The efficacy of the anticancer-liposome formulations were investigated for the viability of normal glial cells (SVGP12) and glioma cell lines (1321N1, Gos-3 and U87-MG) using the proliposome method. On measurement of ATP release by SVGP12, 1321N1, Gos-3 and U87-MG after treatment with anticancer liposomes showed more significant growth inhibition of glioma cell line without effecting the growth of the glial cells. Further experiments are required to determine the mechanism action of anticancer liposome in inhibiting glioma.

Where applicable, experiments conform with Society ethical requirements